199 related articles for article (PubMed ID: 31405846)
21. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
[TBL] [Abstract][Full Text] [Related]
22. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis.
Teitz T; Inoue M; Valentine MB; Zhu K; Rehg JE; Zhao W; Finkelstein D; Wang YD; Johnson MD; Calabrese C; Rubinstein M; Hakem R; Weiss WA; Lahti JM
Cancer Res; 2013 Jul; 73(13):4086-97. PubMed ID: 23536557
[TBL] [Abstract][Full Text] [Related]
23. Neuroblastoma patient-derived cultures are enriched for a mesenchymal gene signature and reflect individual drug response.
Hee E; Wong MK; Tan SH; Choo Z; Kuick CH; Ling S; Yong MH; Jain S; Lian DWQ; Ng EHQ; Yong YFL; Ren MH; Syed Sulaiman N; Low SYY; Chua YW; Syed MF; Lim TKH; Soh SY; Iyer P; Seng MSF; Lam JCM; Tan EEK; Chan MY; Tan AM; Chen Y; Chen Z; Chang KTE; Loh AHP
Cancer Sci; 2020 Oct; 111(10):3780-3792. PubMed ID: 32777141
[TBL] [Abstract][Full Text] [Related]
24. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Fabian J; Opitz D; Althoff K; Lodrini M; Hero B; Volland R; Beckers A; de Preter K; Decock A; Patil N; Abba M; Kopp-Schneider A; Astrahantseff K; Wünschel J; Pfeil S; Ercu M; Künkele A; Hu J; Thole T; Schweizer L; Mechtersheimer G; Carter D; Cheung BB; Popanda O; von Deimling A; Koster J; Versteeg R; Schwab M; Marshall GM; Speleman F; Erb U; Zoeller M; Allgayer H; Simon T; Fischer M; Kulozik AE; Eggert A; Witt O; Schulte JH; Deubzer HE
Oncotarget; 2016 Oct; 7(41):66344-66359. PubMed ID: 27572323
[TBL] [Abstract][Full Text] [Related]
25. NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.
Suenaga Y; Islam SM; Alagu J; Kaneko Y; Kato M; Tanaka Y; Kawana H; Hossain S; Matsumoto D; Yamamoto M; Shoji W; Itami M; Shibata T; Nakamura Y; Ohira M; Haraguchi S; Takatori A; Nakagawara A
PLoS Genet; 2014 Jan; 10(1):e1003996. PubMed ID: 24391509
[TBL] [Abstract][Full Text] [Related]
26. Immune characterization of pre-clinical murine models of neuroblastoma.
Webb ER; Lanati S; Wareham C; Easton A; Dunn SN; Inzhelevskaya T; Sadler FM; James S; Ashton-Key M; Cragg MS; Beers SA; Gray JC
Sci Rep; 2020 Oct; 10(1):16695. PubMed ID: 33028899
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors.
Vaughan L; Clarke PA; Barker K; Chanthery Y; Gustafson CW; Tucker E; Renshaw J; Raynaud F; Li X; Burke R; Jamin Y; Robinson SP; Pearson A; Maira M; Weiss WA; Workman P; Chesler L
Oncotarget; 2016 Sep; 7(36):57525-57544. PubMed ID: 27438153
[TBL] [Abstract][Full Text] [Related]
28. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
29. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo.
Faisal A; Vaughan L; Bavetsias V; Sun C; Atrash B; Avery S; Jamin Y; Robinson SP; Workman P; Blagg J; Raynaud FI; Eccles SA; Chesler L; Linardopoulos S
Mol Cancer Ther; 2011 Nov; 10(11):2115-23. PubMed ID: 21885865
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
31. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
[TBL] [Abstract][Full Text] [Related]
33. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome profiling of caspase-2 deficient EμMyc and Th-MYCN mouse tumors identifies distinct putative roles for caspase-2 in neuronal differentiation and immune signaling.
Dorstyn L; Hackett-Jones E; Nikolic A; Norris MD; Lim Y; Toubia J; Haber M; Kumar S
Cell Death Dis; 2019 Jan; 10(2):56. PubMed ID: 30670683
[TBL] [Abstract][Full Text] [Related]
35. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
36. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
37. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
38. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model.
Waldeck K; Cullinane C; Ardley K; Shortt J; Martin B; Tothill RW; Li J; Johnstone RW; McArthur GA; Hicks RJ; Wood PJ
Int J Cancer; 2016 Jul; 139(1):194-204. PubMed ID: 26914605
[TBL] [Abstract][Full Text] [Related]
39. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
[TBL] [Abstract][Full Text] [Related]
40. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]